← Leaderboards
Ellen Kraig
University Of Texas Hlth Sci Ctr San Ant
$5,692,630
Attributed
$7,930,649
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,930,649 · 14
By mechanism
R01$4,077,595 · 4
U01$2,296,638 · 1
R21$1,266,292 · 3
P51$290,124 · 6
Top collaborators
- Dean L Kellogg4 shared
- Qunfeng Dong2 shared
- Brett C Ginsburg2 shared
- Cun Li2 shared
- Mark J Nijland2 shared
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- Arlan G. Richardson$23,573,173
- James F Nelson$5,250,239
- Yousin Suh$23,055,406
- Paula K Shireman$18,405,170
- Dean L Kellogg$3,465,112
Others in their field
Top investigators on “Elderly”
- Charles A Coltman · Southwest Oncology Group$158,376,564
- Richard L Schilsky · University Of Chicago$122,071,723
- Michael W Weiner · Northern California Institute Res &Educ$99,760,701
- Monica M Bertagnolli · Strang Cancer Prevention Center$99,246,201
- Richard Mayeux · Columbia University Health Sciences$83,247,500
- Peter Gordon Gillespie · Oregon Health And Science University$80,983,248
Research focus
ElderlyCytokineImmunityAgingImmune ResponseAge EffectPapioNonhuman PrimateMalignant NeoplasmsImmuneVaccinesInsightImmune FunctionPredispositionAge RelatedBaseCommunicable DiseasesVaccine EfficacyAntigensLeftAnimalsRodentT-LymphocyteGrant
Grant awards (26)
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An exploratory PK/PD study of mTOR inhibition in older human subjects$1,232,321
U01 · FY2025 · AG · contact PI
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An exploratory PK/PD study of mTOR inhibition in older human subjects$1,064,317
U01 · FY2024 · AG · contact PI
The Paternal Age Effect - Enhanced Germ Cell Mutagenesis Modulated by the TRP53/APE1/MDM2 Tumor Suppressor Axis$355,712
R01 · FY2024 · AG · contact PI
An innovative proof-of-concept approach to identify age-modulating drugs capable of reversing inflammation and re-setting the epigenetic clock$193,438
R21 · FY2021 · AG · contact PI
An innovative proof-of-concept approach to identify age-modulating drugs capable of reversing inflammation and re-setting the epigenetic clock$231,000
R21 · FY2020 · AG · contact PI
Maternal obesity and immune developmental programming, role of the microbiome$203,429
R21 · FY2017 · HD · contact PI
Maternal obesity and immune developmental programming, role of the microbiome$239,258
R21 · FY2016 · HD · contact PI
Maternal nutrient restriction: Effects on offspring immune function$212,813
R21 · FY2013 · HD · contact PI
Maternal nutrient restriction: Effects on offspring immune function$186,354
R21 · FY2012 · HD · contact PI
Effects of aging on vaccine efficacy in non human primate models$550,302
R01 · FY2011 · AG · contact PI
EFFECTS OF AGING ON VACCINE EFFICACY IN NONHUMAN PRIMATE MODELS$164,698
P51 · FY2011 · RR · contact PI
Effects of aging on vaccine efficacy in non human primate models$424,224
R01 · FY2010 · AG · contact PI
EFFECTS OF AGING ON VACCINE EFFICACY IN NONHUMAN PRIMATE MODELS$71,421
P51 · FY2010 · RR · contact PI
THE EFFECTS OF AGING IN NONHUMAN PRIMATES$2,132
P51 · FY2010 · RR · contact PI
Effects of aging on vaccine efficacy in non human primate models$545,150
R01 · FY2009 · AG · contact PI
Effects of aging on vaccine efficacy in non human primate models$270,579
R01 · FY2009 · AG · contact PI
THE EFFECTS OF AGING IN NONHUMAN PRIMATES$1,926
P51 · FY2009 · RR · contact PI
NOVEL APPROACH TO CHLAMYDIA VACCINE DEVELOPMENT$311,478
R01 · FY2007 · AI · contact PI
NOVEL APPROACH TO CHLAMYDIA VACCINE DEVELOPMENT$320,781
R01 · FY2006 · AI · contact PI
USE OF RECALL IMMUNITY TO ENHANCE VACCINE EFFICACY IN THE ELDERLY$27,663
P51 · FY2006 · RR · contact PI
NOVEL APPROACH TO CHLAMYDIA VACCINE DEVELOPMENT$328,500
R01 · FY2005 · AI
USE OF RECALL IMMUNITY TO ENHANCE VACCINE EFFICACY IN THE ELDERLY$22,284
P51 · FY2005 · RR
NOVEL APPROACH TO CHLAMYDIA VACCINE DEVELOPMENT$328,500
R01 · FY2004 · AI
T CELL RESPONSE TO A PERIODONTAL PATHOGEN$218,298
R01 · FY2002 · DE
T CELL RESPONSE TO A PERIODONTAL PATHOGEN$215,193
R01 · FY2001 · DE
T CELL RESPONSE TO A PERIODONTAL PATHOGEN$208,878
R01 · FY2000 · DE